. 2012 Jun;7(6):965–973. doi: 10.2215/CJN.11191111

Table 1.

Comparison of the groups in terms of serum osteoprotegerin, receptor activator of NF-κB ligand, and osteoprotegerin/receptor activator of NF-κB ligand ratio

	HD Patients (n=78)	CKD Stage 4 Patients (n=44)	Control Patients (n=42)	P Values
OPG (pmol/L; range)	15.11±8.50^a^,^b (4.94–38.38)	9.33±4.29^c (4.62–19.61)	5.82±1.39 (3.58–9.35)	<0.001^a
		9.33±4.29^c (4.62–19.61)		<0.001^b
				0.03^c
RANKL (pmol/L; IQR)	145 (110–235)^a^,^b	205 (153–365)	222 (141–364)	0.007^a
RANKL (pmol/L; IQR)	145 (110–235)^a^,^b	205 (153–365)	222 (141–364)	0.02^b
OPG/RANKL (IQR)	0.07 (0.04–0.21)^a^,^b	0.05 (0.02–0.07)	0.02 (0.01–0.04)	<0.001^a
OPG/RANKL (IQR)	0.07 (0.04–0.21)^a^,^b	0.05 (0.02–0.07)	0.02 (0.01–0.04)	<0.001^b

For variables that are not normally distributed, median (interquartile range) was used. HD, hemodialysis; OPG, osteoprotegerin; RANKL, receptor activator of NF-κB ligand; IQR, interquartile range.

HD patients are different from patients with CKD stage 4.

HD patients are different from controls.

Patients with CKD stage 4 are different from controls.